Biblio
Found 50 results
Filters: Author is Largent-Milnes, Tally M [Clear All Filters]
.
2017. Remote Ischemic Conditioning Preserves Cognition and Motor Coordination in a Mouse Model of Traumatic Brain Injury.. J Trauma Acute Care Surg.
.
2017. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.. Neuropharmacology. 116:59-70.
.
2017. Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.. Pain. 158(9):1733-1742.
.
2016. Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain.. Pain. 157(12):2709-2721.
.
2016. The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain.. Pain. 157(11):2605-2616.
.
2016. Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations.. Bioorg Med Chem Lett. 26(1):222-7.
.
2016. Structure-Activity Relationships of [des-Arg(7)]Dynorphin A Analogues at the κ Opioid Receptor.. J Med Chem. 59(22):10291-10298.
.
2015. Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives.. Bioorg Med Chem Lett. 25(20):4683-8.
.
2015. Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.. Bioorg Med Chem. 23(18):6185-94.
.
2015. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.. J Med Chem. 58(21):8573-83.
.
2015. Temperature differentially facilitates spontaneous but not evoked glutamate release from cranial visceral primary afferents.. PLoS One. 10(5):e0127764.
.
2015. Use of Animal Models in Understanding Cancer-induced Bone Pain.. Cancer Growth Metastasis. 8(Suppl 1):47-62.
.
2014. Animal models for opioid addiction drug discovery.. Expert Opin Drug Discov. 9(11):1345-54.
.
2014. Capsaicin-responsive corneal afferents do not contain TRPV1 at their central terminals in trigeminal nucleus caudalis in rats.. J Chem Neuroanat. 61-62:1-12.
.
2014. External QX-314 inhibits evoked cranial primary afferent synaptic transmission independent of TRPV1.. J Neurophysiol. 112(11):2697-706.
.
2014. Physiological temperatures drive glutamate release onto trigeminal superficial dorsal horn neurons.. J Neurophysiol. 111(11):2222-31.
.
2013. Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.. J Bone Miner Res. 28(1):92-107.
.
2013. Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.. Bioorg Med Chem Lett. 23(17):4975-8.
.
2012. Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.. J Neuroimmunol. 244(1-2):23-31.
.
2012. Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.. Eur J Pharmacol. 684(1-3):64-70.
.
2011. Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.. J Med Chem. 54(7):2029-38.
.
2011. Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.. Brain Res. 1395:1-11.
.
2010. A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.. Life Sci. 86(17-18):646-53.
.
2010. Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin Ther Pat. 20(3):291-305.
.
2008. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.. J Pain. 9(8):700-13.